FDMT Stock Overview
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors.
4D Molecular Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.96|
|52 Week High||US$36.14|
|52 Week Low||US$5.32|
|1 Month Change||-9.49%|
|3 Month Change||-56.47%|
|1 Year Change||-70.94%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-82.82%|
Recent News & Updates
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|FDMT||US Biotechs||US Market|
Return vs Industry: FDMT underperformed the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: FDMT underperformed the US Market which returned -21.2% over the past year.
|FDMT Average Weekly Movement||11.0%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: FDMT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: FDMT's weekly volatility (11%) has been stable over the past year.
About the Company
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease.
4D Molecular Therapeutics Fundamentals Summary
|FDMT fundamental statistics|
Is FDMT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|FDMT income statement (TTM)|
|Cost of Revenue||US$67.97m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.52|
|Net Profit Margin||-470.82%|
How did FDMT perform over the long term?See historical performance and comparison
Is FDMT undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for FDMT?
Other financial metrics that can be useful for relative valuation.
|What is FDMT's n/a Ratio?|
Price to Sales Ratio vs Peers
How does FDMT's PS Ratio compare to its peers?
|FDMT PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
RIGL Rigel Pharmaceuticals
STRO Sutro Biopharma
FDMT 4D Molecular Therapeutics
Price-To-Sales vs Peers: FDMT is expensive based on its Price-To-Sales Ratio (13x) compared to the peer average (4.1x).
Price to Earnings Ratio vs Industry
How does FDMT's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: FDMT is good value based on its Price-To-Sales Ratio (13x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is FDMT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||13x|
|Fair PS Ratio||0.03x|
Price-To-Sales vs Fair Ratio: FDMT is expensive based on its Price-To-Sales Ratio (13x) compared to the estimated Fair Price-To-Sales Ratio (0x).
Share Price vs Fair Value
What is the Fair Price of FDMT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate FDMT's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate FDMT's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate FDMT's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is 4D Molecular Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: FDMT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: FDMT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: FDMT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: FDMT's revenue is expected to decline over the next 3 years (-22.3% per year).
High Growth Revenue: FDMT's revenue is forecast to decline over the next 3 years (-22.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if FDMT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has 4D Molecular Therapeutics performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: FDMT is currently unprofitable.
Growing Profit Margin: FDMT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: FDMT is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.
Accelerating Growth: Unable to compare FDMT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: FDMT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: FDMT has a negative Return on Equity (-27.44%), as it is currently unprofitable.
Discover strong past performing companies
How is 4D Molecular Therapeutics's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: FDMT's short term assets ($243.0M) exceed its short term liabilities ($12.1M).
Long Term Liabilities: FDMT's short term assets ($243.0M) exceed its long term liabilities ($16.8M).
Debt to Equity History and Analysis
Debt Level: FDMT is debt free.
Reducing Debt: FDMT has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FDMT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: FDMT has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 44% each year.
Discover healthy companies
What is 4D Molecular Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate FDMT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FDMT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FDMT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FDMT's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FDMT has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Kirn (59 yo)
Dr. David H. Kirn, M.D., co-founded 4D Molecular Therapeutics, Inc. in 2013 and has been its Chief Executive Officer since September 12, 2013. Dr. Kirn has been President of 4D Molecular Therapeutics, Inc....
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD5.20M) is above average for companies of similar size in the US market ($USD1.83M).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
Experienced Management: FDMT's management team is considered experienced (2.1 years average tenure).
Experienced Board: FDMT's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.8%.
4D Molecular Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: 4D Molecular Therapeutics, Inc.
- Ticker: FDMT
- Exchange: NasdaqGS
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$224.806m
- Shares outstanding: 32.30m
- Website: https://www.4dmoleculartherapeutics.com
Number of Employees
- 4D Molecular Therapeutics, Inc.
- 5858 Horton Street
- Suite 455
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/03 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.